Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy

International Journal of Cancer

Volumn 128, Issue 10, 2011, Pages 2470-2480

  Lee, Jue Yeon ^a   Choi, Young Suk ^a   Suh, Jin Sook ^a   Kwon, Young Min ^b   Yang, Victor C ^b   Lee, Seung Jin ^c   Chung, Chong Pyoung ^a   Park, Yoon Jeong ^a  

^a Seoul National University   (South Korea)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Ewha Womans University   (South Korea)

Author keywords

Cell penetrating peptide; chitosan conjugate; doxorubicin; TAT; tumor

Indexed keywords

CHITOSAN; DOXORUBICIN; TRANSACTIVATOR PROTEIN;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; CHITOSAN; DOXORUBICIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FLOW CYTOMETRY; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; NEOPLASMS, EXPERIMENTAL; TRANSCRIPTION FACTORS;

EID: 79953169511     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25578     Document Type: Article

References (43)

1. Malugin A, Kopeckova P, Kopecek J,. HPMA copolymer-bound doxorubicin induces apoptosis in human ovarian carcinoma cells by a Fas-independent pathway. Mol Pharm 2004; 1: 174-82.
2. Malugin A, Kopeckova P, Kopecek J,. HPMA copolymer-bound doxorubicin induces apoptosis in ovarian carcinoma cells by the disruption of mitochondrial function. Mol Pharm 2006; 3: 351-61. (Pubitemid 44021441)
3. Cheng J, Khin KT, Davis ME,. Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates. Mol Pharm 2004; 1: 183-93.
4. Kopecek J, Kopeckova P, Minko T, Lu Z,. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000; 50: 61-81. (Pubitemid 30326689)
5. Maeda H, Seymour LW, Miyamoto Y,. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992; 3: 351-62.
6. Duncan R,. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 1992; 3: 175-210.
7. Kang H, DeLong R, Fisher MH, Juliano RL,. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res 2005; 22: 2099-106. (Pubitemid 41821589)
8. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R,. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000; 18: 410-4. (Pubitemid 30217528)
9. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF,. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285: 1569-72. (Pubitemid 29420581)
10. Liu L, Venkatraman SS, Yang YY, Guo K, Lu J, He B, Moochhala S, Kan L,. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Biopolymers 2008; 90: 617-23.
11. Liang JF, Yang VC,. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg Med Chem Lett 2005; 15: 5071-5. (Pubitemid 41400186)
12. Liang JF, Yang VC,. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun 2005; 335: 734-8. (Pubitemid 41188260)
13. Park YJ, Chang LC, Liang JF, Moon C, Chung CP, Yang VC,. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. Faseb J 2005; 19: 1555-7. (Pubitemid 41279029)
14. Lee KY, Kim JH, Kwon IC, Jeong SY,. Self-aggregates of deoxycholic acid modified chitosan as a novel carrier of adriamycin. Colloid Polym Sci 2000; 278: 1216-9.
15. Ruel-Gariepy E, Leclair G, Hildgen P, Gupta A, Leroux JC,. Thermosensitive chitosan-based hydrogel containing liposomes for the delivery of hydrophilic molecules. J Control Release 2002; 82: 373-83. (Pubitemid 34880191)
16. Kim YH, Gihm SH, Park CR, Lee KY, Kim TW, Kwon IC, Chung H, Jeong SY,. Structural characteristics of size-controlled self-aggregates of deoxycholic acid-modified chitosan and their application as a DNA delivery carrier. Bioconjug Chem 2001; 12: 932-8.
17. Koping-Hoggard M, Tubulekas I, Guan H, Edwards K, Nilsson M, Varum KM, Artursson P,. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther 2001; 8: 1108-21. (Pubitemid 32962708)
18. Roy K, Mao HQ, Huang SK, Leong KW,. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5: 387-91. (Pubitemid 29180575)
19. Dufes C, Schatzlein AG, Tetley L, Gray AI, Watson DG, Olivier JC, Couet W, Uchegbu IF,. Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting. Pharm Res 2000; 17: 1250-8.
20. Park YJ, Kim KH, Lee JY, Ku Y, Lee SJ, Min BM, Chung CP,. Immobilization of bone morphogenetic protein-2 on a nanofibrous chitosan membrane for enhanced guided bone regeneration. Biotechnol Appl Biochem 2006; 43: 17-24. (Pubitemid 43059035)
21. Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD,. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol 1990; 27: 13-9.
22. Mitra S, Gaur U, Ghosh PC, Maitra AN,. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001; 74: 317-23. (Pubitemid 32727639)
23. Chang LC, Lee HF, Yang Z, Yang VC,. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization. AAPS PharmSci 2001; 3: E17.
24. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M, Flynn E, Parangi S, Byers HR, Folkman J,. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A 1997; 94: 861-6. (Pubitemid 27074412)
25. Aoki T, Iskandar S, Yoshida T, Takahashi K, Hattori M,. Reduced immunogenicity of beta-lactoglobulin by conjugating with chitosan. Biosci Biotechnol Biochem 2006; 70: 2349-56. (Pubitemid 44656398)
26. Hyung Park J, Kwon S, Lee M, Chung H, Kim JH, Kim YS, Park RW, Kim IS, Bong Seo S, Kwon IC, Young Jeong S,. Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials 2006; 27: 119-26. (Pubitemid 41225375)
27. Lee JY, Choo JE, Choi YS, Shim IK, Lee SJ, Seol YJ, Chung CP, Park YJ,. Effect of immobilized cell-binding peptides on chitosan membranes for osteoblastic differentiation of mesenchymal stem cells. Biotechnol Appl Biochem 2009; 52: 69-77.
28. Yoo HS, Lee JE, Chung H, Kwon IC, Jeong SY,. Self-assembled nanoparticles containing hydrophobically modified glycol chitosan for gene delivery. J Control Release 2005; 103: 235-43. (Pubitemid 40248575)
29. Westermeier R, Gronau S,. Electrophoresis in practice: a guide to methods and applications of DNA and protein separations. 4th Rev. Weinheim: Wiley-VCH, 2005.
30. Liang JF, Li YT, Song H, Park YJ, Naik SS, Yang VC,. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs. J Control Release 2002; 78: 67-79. (Pubitemid 34081854)
31. Syrigos KN, Epenetos AA,. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res 1999; 19: 605-13. (Pubitemid 29168301)
32. Chari RV,. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev 1998; 31: 89-104. (Pubitemid 28191877)
33. Mellman I,. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 1996; 12: 575-625. (Pubitemid 26422725)
34. Niesner U, Halin C, Lozzi L, Gunthert M, Neri P, Wunderli-Allenspach H, Zardi L, Neri D,. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002; 13: 729-36. (Pubitemid 34801114)
35. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J,. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 1994; 91: 664-8. (Pubitemid 24041462)
36. Moon C, Kwon YM, Lee WK, Park YJ, Chang LC, Yang VC,. A novel polyrotaxane-based intracellular delivery system for camptothecin: in vitro feasibility evaluation. J Biomed Mater Res A 2008; 84: 238-46. (Pubitemid 350244265)
37. Nori A, Kopecek J,. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev 2005; 57: 609-36. (Pubitemid 40267695)
38. Wagner E, Ogris M, Zauner W,. Polylysine-based transfection systems utilizing receptor-mediated delivery. Adv Drug Deliv Rev 1998; 30: 97-113. (Pubitemid 28201908)
39. Morris MC, Depollier J, Mery J, Heitz F, Divita G,. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19: 1173-6. (Pubitemid 33115705)
40. Becker-Hapak M, McAllister SS, Dowdy SF,. TAT-mediated protein transduction into mammalian cells. Methods 2001; 24: 247-56. (Pubitemid 32846431)
41. McGrath MS, Rosenblum MG, Philips MR, Scheinberg DA,. Immunotoxin resistance in multidrug resistant cells. Cancer Res 2003; 63: 72-9. (Pubitemid 36070422)
42. Rosenblum MG, Shawver LK, Marks JW, Brink J, Cheung L, Langton-Webster B,. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Clin Cancer Res 1999; 5: 865-74. (Pubitemid 29180839)
43. Eliaz RE, Nir S, Marty C, Szoka FC Jr,. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res 2004; 64: 711-8. (Pubitemid 38120914)